Medical application of GNG2 in prevention or treatment of myocardial infarction

Through drugs and diagnostic products that regulate GNG2 expression, the problems of poor prognosis of acute myocardial infarction and unclear apoptosis mechanism of cardiomyocytes are solved, and the cardiac function after myocardial infarction is significantly improved, providing new targets and diagnostic tools for AMI.

CN118903474APending Publication Date: 2024-11-08GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410965878.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Patients with acute myocardial infarction have poor prognosis, existing treatment methods cannot effectively restore cardiomyocytes, and the apoptosis mechanism of cardiomyocytes is unclear, and there is a lack of effective intervention targets.

Method used

By increasing or inhibiting the expression of the GNG2 gene or protein, drugs and diagnostic products for the prevention or treatment of acute myocardial infarction are prepared by using GNG2 gene, recombinant vectors, host bacteria or specific targeted siRNA to regulate cardiomyocyte apoptosis.

Benefits of technology

In the AMI model, GNG2 expression significantly affects cardiac function. Overexpression of GNG2 can improve cardiac function after myocardial infarction, inhibit or promote cardiomyocyte apoptosis, providing new targets and diagnostic tools for AMI, with clinical transformation prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903474A_ABST
    Figure CN118903474A_ABST
Patent Text Reader

Abstract

The invention provides the effect of GNG2 in the occurrence and development process of AMI for the first time, discloses medical application of GNG2 overexpression in drugs for treating AMI prognosis, and belongs to the field of biological medicine. A large number of experiments prove that GNG2 expression in an AMI model is obviously improved. A GNG2 mouse in-vivo overexpression or low expression model is constructed by adopting a caudal vein injection AAV virus method, and the result shows that the mouse in-vivo overexpression GNG2 obviously improves the cardiac function after AMI. In in vitro cytology, when the H9C2 / NRCMs are subjected to hypoxia stimulation by CoCl2, the expression of the GNG2 protein is obviously increased. Low expression of GNG2 promotes hypoxia-induced myocardial cell apoptosis; on the contrary, the overexpressed GNG2 inhibits hypoxia-induced myocardial cell apoptosis. The results show that the GNG2 plays an important regulation and control role in the occurrence and development process of the AMI, and can be a new target for preventing or treating the AMI. The content disclosed by the invention can be applied to preparation of products for diagnosis, treatment and the like of AMI, and has a clinical transformation prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and specifically to the medical use of GNG2 (G-protein gamma subunit 2), and further to the use of inducing GNG2 gene expression or its active fragments in the preparation of medicines for preventing or treating myocardial infarction. Background Art

[0002] Acute myocardial infarction (AMI) is defined as the sudden ischemic death of myocardial tissue. AMI has a high incidence and poor prognosis, which seriously threatens the health of the Chinese people. The latest China Health and Cardiovascular Disease Report pointed out that since 2005, the mortality rate of acute myocardial infarction has been rising rapidly. The mortality rate of AMI in rural areas not only exceeded that in urban areas in 2007, 2009 and 2010, but also increased significantly in rural areas since 2012, and has continued to be higher than the urban level since 2013. In the past few decades, advanced methods such as stent technology and auxiliary drug therapy have been widely studied for the treatment of myocardial infarction, but the prognosis of patients with myocardial infarction is still poor. With the changes in lifestyle and dietary structure, the incidence of myocardial infarction is becoming younger and younger.

[0003] The adult heart of mammals has poor regenerative potential, and the loss of cardiomyocytes cannot be restored after myocardial infarction. Therefore, preventing cardiomyocyte loss will be an effective way to treat myocardial infarction and promote recovery. Recent studies have shown that apoptosis, a type of programmed cell death, promotes the progression of many diseases and leads to organ dysfunction. In myocardial infarction, myocardial apoptosis is the main cause of cardiomyocyte loss and plays a key role in ventricular remodeling and subsequent heart failure. However, cardiomyocyte apoptosis is a very complex pathological process, and the key regulatory molecules are not yet very clear. Therefore, it is crucial to explore the pathogenesis of AMI and find new effective intervention targets from the perspective of cardiomyocyte apoptosis.

[0004] GNG2 is a subunit of the Gβγ-dimer, which forms a heterotrimeric G protein with the Gα subunit. Heterotrimeric G proteins play an important role in cell proliferation, differentiation, and angiogenesis, and are potential molecular targets for the treatment of various diseases. Big data analysis shows that GNG2 plays a vital role in many diseases and biological processes, including Down syndrome, colorectal cancer, and thiopurine metabolism. As part of the heterotrimeric G protein, GNG2 independently inhibits the proliferation and invasion of human malignant melanoma cells. The latest report on GNG2 is its study on breast cancer. Ling Li et al. confirmed that the interaction between GNG2 and muscle RAS oncogene homolog (MRAS) may inhibit Akt and Erk activity, thereby promoting apoptosis of breast cancer cells and inhibiting their proliferation. Importantly, in the screening of key genes for hypertrophic cardiomyopathy, it was found that the expression of GNG2 was significantly different. However, the role and mechanism of GNG2 in ischemic heart disease are still unclear. Summary of the invention

[0005] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a medical use of inducing GNG2 expression or promoting its active fragments for preventing or treating AMI. A large number of experiments have shown that GNG2 plays an important regulatory role in the occurrence and development of AMI and may be a new target for the prevention or treatment of AMI.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions.

[0007] The invention discloses a medicine for treating the prognosis of acute myocardial infarction, characterized in that the medicine comprises an agent for increasing the expression amount of GNG2 gene or protein.

[0008] Furthermore, the reagent for increasing the expression level of the GNG2 gene or protein includes the GNG2 gene, or a plasmid containing the GNG2 gene coding region, or a recombinant vector containing the GNG2 gene coding region, or a host bacteria containing the recombinant vector, or a cell containing the recombinant vector.

[0009] Furthermore, the drug also includes a pharmaceutically acceptable carrier; the dosage form of the drug is a pharmaceutically acceptable dosage form.

[0010] The present invention also discloses a reagent for inhibiting apoptosis of myocardial cells after hypoxia, characterized in that the reagent comprises a reagent for increasing the expression amount of GNG2 gene or protein.

[0011] Furthermore, the reagent for increasing the expression level of the GNG2 gene or protein includes the GNG2 gene, or a plasmid containing the GNG2 gene coding region, or a recombinant vector containing the GNG2 gene coding region, or a host bacteria containing the recombinant vector, or a cell containing the recombinant vector.

[0012] The present invention also discloses a reagent for promoting apoptosis of myocardial cells after hypoxia, characterized in that the reagent comprises a reagent for inhibiting the expression amount of GNG2 gene or protein.

[0013] Furthermore, the reagent for inhibiting the expression of the GNG2 gene or protein includes siRNA specifically targeting the GNG2 gene, and the nucleotide sequence of the siRNA is shown in SEQ ID NO.5.

[0014] The present invention also discloses the use of a detection reagent for the expression level of the GNG2 gene or its encoded protein in the preparation of an auxiliary diagnosis product for acute myocardial infarction.

[0015] Furthermore, the product detects the expression level of the GNG2 gene or its encoded protein in a sample by reverse transcription PCR, real-time quantitative PCR, chip, high-throughput sequencing platform, immunohistochemical staining or enzyme-linked immunosorbent assay.

[0016] Furthermore, the product contains specific primers for amplifying the GNG2 gene, probes that hybridize with the nucleotide sequence of the GNG2 gene, or antibodies that specifically bind to the GNG2 protein; the specific primer sequences of the GNG2 gene are as shown in SEQ ID NO.1~2.

[0017] Compared with the prior art, the beneficial effects of the present invention are as follows.

[0018] The present invention proposes for the first time the role of GNG2 in the occurrence and development of AMI, and discloses the medical use of GNG2 overexpression in drugs for treating AMI prognosis. The inventors found through a large number of experiments that GNG2 expression was significantly increased in the AMI model. A GNG2 overexpression or underexpression model in mice was constructed by tail vein injection of AAV virus, and it was found that overexpression of GNG2 in mice significantly improved cardiac function after AMI. In in vitro cytology, when H9C2 / NRCMs were given CoCl2 hypoxia stimulation, GNG2 protein expression was significantly increased. Low expression of GNG2 promotes hypoxia-induced cardiomyocyte apoptosis; conversely, overexpression of GNG2 inhibits hypoxia-induced cardiomyocyte apoptosis. The above results show that GNG2 plays an important regulatory role in the occurrence and development of AMI and may be a new target for the prevention or treatment of AMI. The present invention can be used in the preparation of products such as the diagnosis and treatment of AMI, and has certain clinical transformation prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 In the AMI model of C57BL / 6J mice, GNG2 expression was upregulated. p <0.05 vs. sham group; *** p <0.001vs. sham group). A is the statistical graph of RT-PCR results; B and C are western blot results and their statistical graphs.

[0020] Figure 2 Overexpression of GNG2 in C57BL / 6J mice improves cardiac function after AMI. AE is the ultrasound image and cardiac function statistics of the mouse heart 28 days after the myocardial infarction model was established in mice overexpressing GNG2; F is the H&E staining, MASSON staining and WGA staining 28 days after the myocardial infarction model was established in mice overexpressing GNG2. (**** p <0.0001 vs. sham group; # p <0.05vs. AAV-NC+AMI group;## p <0.01 vs. AAV-NC+AMI group).

[0021] Figure 3 GNG2 overexpression inhibits hypoxia-induced apoptosis in H9C2 cardiomyocytes. AE are the western blot results and statistical graphs of H9C2 cardiomyocytes overexpressing GNG2 and stimulating CoCl2; F and G are the TUNEL staining results and statistical graphs of H9C2 cardiomyocytes overexpressing GNG2 and stimulating CoCl2 (* p <0.05 vs. AdNC group; ** p <0.01 vs. AdNC group; *** p <0.001 vs. AdNC group; # p <0.05 vs. AdNC + CoCl2 group; ### p <0.001vs.AdNC+CoCl2 group).

[0022] Figure 4 GNG2 low expression promotes hypoxia-induced apoptosis of H9C2 cardiomyocytes. AE are the western blot results and statistical graphs of H9C2 cardiomyocytes with GNG2 low expression and CoCl2 stimulation; F and G are the TUNEL staining results and statistical graphs of H9C2 cardiomyocytes with GNG2 low expression and CoCl2 stimulation (** p <0.01 vs. siNC group; *** p <0.001 vs. siNC group; #p <0.05 vs.siNC + CoCl2 group; ## p <0.01 vs.siNC + CoCl2 group; ### p <0.001 vs.siNC+CoCl2 group). DETAILED DESCRIPTION

[0023] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If the specific conditions are not specified in the examples, they are carried out according to conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially. The present invention is processed using the GraphPad Prism 8.0 software package, and p < 0.05 is considered statistically significant.

[0024] Example 1: In the AMI model established with C57BL / 6J mice, the expression of GNG2 in myocardial tissue was upregulated.

[0025] 1. Experimental animals and their husbandry.

[0026] Experimental animal species, sex, age and source: C57BL / 6J mice, male, 8 weeks old. C57BL / 6J mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. Mice were raised in a specific pathogen free (SPF) animal room with a room temperature of (22±2)℃, a humidity of 45%~70%, a 12-h light cycle, and free access to food and water.

[0027] 2. Establishment of AMI model in C57BL / 6J mice.

[0028] C57BL / 6J mice were randomly divided into a control group and an experimental group, with 8 mice in each group. After anesthesia, the mice were depilated and skinned, and fixed on the operating table in a supine position; a cannula was inserted into the mouse's mouth and connected to a ventilator. The success of the cannula was determined based on the mouse's chest respiratory movement and the ventilator frequency. After disinfection with iodine tincture, the skin was cut along the left axilla to the xiphoid process of the sternum, and the pectoralis major and pectoralis minor muscles were bluntly separated. About 0.5 cm was cut along the third and fourth intercostal spaces on the left side at the most obvious part of the heart beat, and the pericardium and attached connective tissue were carefully torn apart. The large blood vessels on the surface of the heart could be clearly seen, and the left anterior descending branch of the coronary artery was ligated with a 6-0 surgical suture. If the ligation was successful, the anterior wall of the ventricle could be seen to gradually turn pale. After squeezing out the thoracic gas, the chest wall and the skin at the wound were sutured with a 4-0 suture; the postoperative mice were connected with a small animal electrocardiograph, and when the ST segment elevation exceeded 50%, the model was successfully established. The expression levels of GNG2 in the AMI group and sham group were detected 1, 3, 7, and 28 days after myocardial infarction.

[0029] 3. The fluorescence real-time quantitative PCR (Real-time PCR) method was used to detect the expression of GNG2 in the heart tissue of the AMI model.

[0030] (1) Extraction of RNA from cardiac tissue.

[0031] A. Mouse heart tissue was placed in an RNase-free EP tube, 1 mL of Trizol was added, and three RNase-free grinding beads were added. The tissue was ground in a tissue grinding homogenizer for 120 s at 70 Hz.

[0032] B. Place at room temperature for 5 minutes, add 1 / 5 of chloroform, then turn it upside down to mix well and let it stand for 15 minutes.

[0033] C.10000rpm, 4℃, centrifuge for 10min.

[0034] D. Aspirate the supernatant, add an equal volume of isopropanol, invert and mix, and let stand at room temperature for 10 min.

[0035] E. Centrifuge at 10,000 rpm, 4°C for 10 min and discard the supernatant.

[0036] F. Add 1 mL of 75% ethanol and gently shake the centrifuge tube to resuspend the precipitate.

[0037] G. Centrifuge at 10000 rpm, 4°C for 10 min and discard the supernatant.

[0038] H. Allow to dry at room temperature until transparent.

[0039] I. Add 25 μL of enzyme-free water to dissolve RNA.

[0040] (2) Reverse transcription of RNA to cDNA: using Takara reverse transcription kit.

[0041] A. Removal of genomic DNA .

[0042] B. Reverse transcription reaction .

[0043] Reaction conditions: 37°C for 15 min; 85°C for 5 s; 4°C.

[0044] (3) Primer sequence .

[0045] (4) Fluorescence quantitative PCR .

[0046] According to the volume in the table above, prepare 20 μL qPCR reaction system, and set up 3 replicate wells for each group of samples. Reaction conditions: 95℃5min, (95℃5s, 60℃30s, 72℃30s)×40 cycles, 72℃5s, 95℃15s. -△△Ct The expression of each sample was analyzed.

[0047] The results showed that compared with the sham group, the transcription level of GNG2 was increased in the heart tissue of the AMI group mice ( Figure 1 A).

[0048] 4. The Western blot method was used to detect the expression of GNG2 in the heart tissue of AMI mice.

[0049] In order to clarify the role of GNG2 in AMI, the expression of GNG2 in cardiac tissue was detected by western blot. The hearts of the experimental group and the control group were retained, and an appropriate amount of protein lysis buffer was added. The cells were lysed on ice for 30 minutes and mixed every 5 minutes. The cells were centrifuged at 4°C, 12000g for 20 minutes, and the supernatant was collected as the total tissue protein. The protein concentration was determined by the BCA colorimetric kit. The protein lysis buffer was used and diluted to a final concentration of 3 mg / mL. Then 4× loading buffer was added in proportion, and after sufficient mixing, it was boiled for 5 minutes in a 100°C water bath, and centrifuged at 12000g for 30 seconds at room temperature. 20 μg of protein sample was added to each sample well, the power was turned on, and electrophoresis was started. The following voltage and time were followed: 100V voltage, 30 minutes, 120V voltage, 60 minutes, and the power was turned off after bromophenol blue was electrophoresed to the bottom of the glass plate. The sample was transferred to the PVDF membrane at a voltage of 90V for 2 hours. The PVDF membrane was placed in 5% milk blocking solution for 1 hour, and then the primary antibody was added and incubated overnight at 4°C. GNG2 (Proteintech) and GAPDH (Cell Signaling Technology) were used as primary antibodies, and horseradish peroxidase-labeled goat anti-mouse (or anti-rabbit) antibodies (Cell Signaling Technology) were used as secondary antibodies. The ECL kit (Amersham) was used for luminescence development. The size of the GNG2 antibody is about 10 kDa, and the size of the GAPDH antibody is about 37 kDa. ImageJ 1.51 software was used to measure the gray value of the bands and perform statistical analysis.

[0050] The results showed that compared with the sham group, the expression of GNG2 protein in the heart tissue of the AMI group mice was significantly increased ( Figure 1 B, C).

[0051] The above results all show that GNG2 is upregulated in AMI tissues, suggesting that GNG2 may be involved in the occurrence and development of AMI.

[0052] Example 2: Overexpression of GNG2 in mice improves cardiac function after AMI.

[0053] 1. C57BL / 6J mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. The breeding conditions were the same as those in Example 1.

[0054] 2. Construct GNG2 overexpression mice.

[0055] In order to verify the effect of GNG2 on cardiac function and cardiac remodeling after AMI in vivo, adeno-associated virus (AAV-cTnT-GNG2) overexpressing GNG2 in the heart and its negative control AAV-cTnT-NC were constructed by Heyuan Biotechnology (Shanghai) Co., Ltd. The heart-specific overexpression of GNG2 mice was constructed in vivo by tail vein injection.

[0056] 3. Establishment of AMI model in mice overexpressing GNG2.

[0057] 21 days after the tail vein injection of AAV-cTnT-GNG2 and its negative control virus, the successful overexpression of GNG2 was detected by western blot and RT-PCR. The myocardial infarction model was constructed, and the specific experimental method was the same as in Example 1.

[0058] 4. Ultrasound imaging to measure cardiac function.

[0059] Before ultrasound detection, hair removal cream was used to remove the chest hair of mice, and isoflurane gas was used to slightly anesthetize the mice, and the heart rate of the mice was kept at 450-550 beats / min. Using the Vevo 2100 small animal ultrasound detection system, after applying coupling agent on the chest and upper abdomen of the mice, M-mode echocardiographic records of 10 cardiac cycles were obtained under the guidance of a two-dimensional probe. The two-dimensional image of the left ventricle was collected on the short-axis view of the left ventricle, and the pictures were retained to measure various cardiac function indicators.

[0060] The results showed that compared with the AAV-cTnT-NC group, the cardiac function of mice in the AAV-cTnT-NC+AMI group was significantly reduced. Compared with the AAV-cTnT-NC+AMI group, the cardiac function of the AAV-cTnT-GNG2+AMI group was significantly improved. Figure 2 AE) 5. HE staining was used to detect the gross morphology of the heart.

[0061] Heart tissues from AAV-cTnT-NC, AAV-cTnT-NC+AMI, AAV-cTnT-GNG2, and AAV-cTnT-GNG2+AMI groups 28 days after establishment of myocardial infarction models were collected and subjected to H&E staining.

[0062] The specific steps are as follows.

[0063] (1) Preparation of paraffin sections.

[0064] A. Collection: Place the mouse heart in 4% paraformaldehyde solution overnight.

[0065] B. Dehydration: Dehydration was performed according to different alcohol concentrations: 70% alcohol for 2 hours, 80% alcohol for 2 hours, 90% alcohol for 2 hours, 95% alcohol I for 4 hours, 95% alcohol II overnight, 100% alcohol I for 1.5 hours, and 100% alcohol II for 1.5 hours.

[0066] C. Transparency: Soak the tissue block in xylene I solution for 1 hour, then take it out and soak it in xylene II solution for 1 hour.

[0067] D. Wax immersion: overnight in paraffin I, 1 hour in paraffin II, and 1 hour in paraffin III.

[0068] E. Embedding: Embed the tissue blocks in paraffin and keep at room temperature.

[0069] F. Sectioning: Slice the tissue block with a paraffin slicer to a thickness of 3 μm and mount the sections on glass slides.

[0070] G. Drying and baking the slides: Place the slides in a 60℃ slide dryer for 1 hour, then place the slides in a 65℃ oven for 48 hours.

[0071] (2) Dewaxing of sections: Place the sections in the following reagents according to the steps: xylene I for 20 min, xylene II for 20 min, 95% alcohol I for 15 min, 95% alcohol II for 15 min, 90% alcohol for 10 min, 80% alcohol for 5 min, 70% alcohol for 5 min, and finally place in distilled water for 30 min.

[0072] (3) Nuclear staining.

[0073] A. Immerse the sections in hematoxylin solution for 20 minutes.

[0074] B. Place the paraffin sections in 1% hydrochloric acid for 30 seconds for differentiation and rinse with running water.

[0075] C. Place the paraffin sections in ammonia water for 30 seconds to turn the cell nuclei blue, and then rinse with running water.

[0076] (4) Cytoplasmic staining: Place the paraffin sections in a water-soluble eosin solution for 5 minutes, stain, and rinse with running water.

[0077] (5) Transparency: Place the paraffin sections in the following reagents in order: 80% alcohol for 5 min, 90% alcohol for 5 min, 100% alcohol I for 5 min, 100% alcohol II for 5 min, xylene I for 5 min, and xylene II for 5 min.

[0078] (6) Sealing: Place the paraffin sections in a fume hood to dry and use neutral resin to seal the sections.

[0079] (7) Observe the H&E staining results under a microscope and take photos.

[0080] The results showed that compared with the AAV-cTnT-NC group, the hearts of mice in the AAV-cTnT-NC+AMI group were significantly enlarged; compared with the AAV-cTnT-NC+AMI group, the heart remodeling of mice in the AAV-cTnT-GNG2+AMI group was not obvious (e.g. Figure 2 F).

[0081] 6. MASSON staining was used to detect myocardial fibrosis.

[0082] Heart tissues were collected from AAV-cTnT-NC, AAV-cTnT-NC+AMI, AAV-cTnT-GNG2, and AAV-cTnT-GNG2+AMI groups 28 days after the establishment of the myocardial infarction model, and MASSON staining was performed. The specific steps are as follows.

[0083] (1) Dewaxing of sections: Same as HE staining (steps 1 and 2).

[0084] (2) Staining was performed according to the procedure of the MASSON staining solution (Solebo, China) in the kit.

[0085] (3) Transparency and sealing: Same as H&E staining.

[0086] The results showed that compared with the AAV-cTnT-NC group, the cardiac fibrosis of mice in the AAV-cTnT-NC+AMI group was significantly increased; compared with the AAV-cTnT-NC+AMI group, the degree of cardiac fibrosis of mice in the AAV-cTnT-GNG2+AMI group was improved (e.g. Figure 2 F).

[0087] 7. WGA staining was used to detect the size of cardiomyocytes.

[0088] Heart tissues were collected from AAV-cTnT-NC, AAV-cTnT-NC+AMI, AAV-cTnT-GNG2, and AAV-cTnT-GNG2+AMI groups 28 days after the establishment of the myocardial infarction model, and WGA staining was performed. The specific steps are as follows.

[0089] (1) Dewaxing of sections: Same as WGA staining (steps 1 and 2).

[0090] (2) Antigen retrieval solution (Solabo, China) for 1 h.

[0091] (3) Incubate in WGA staining solution (Sigma) at 37°C in the dark for 1 h and then wash with water.

[0092] (4) Stain nuclei with DAPI and wash with water.

[0093] (5) Seal the slides with fluorescent mounting solution and let them dry.

[0094] The results showed that compared with the AAV-cTnT-NC group, the cardiac myocardial cells of the mice in the AAV-cTnT-NC+AMI group were significantly enlarged; compared with the AAV-cTnT-NC+AMI group, the cardiac myocardial cells of the mice in the AAV-cTnT-GNG2+AMI group were not significantly enlarged (e.g. Figure 2 F).

[0095] Example 3: GNG2 overexpression inhibits cardiomyocyte apoptosis after hypoxia.

[0096] 1. Overexpression of GNG2 in H9C2 cardiomyocytes and establishment of hypoxia model.

[0097] In order to overexpress GNG2 in H9C2 cardiomyocytes, the cells were plated in six-well plates. When the cells grew to 70%-80%, adenovirus containing GNG2 overexpression vector (AdGNG2) and virus with GFP tag (AdNC) as control virus were added to H9C2 cardiomyocytes, cultured in a cell culture incubator at 37℃ and 5% CO2 for 6-8h, and then 600µM CoCl2 was added and cultured for another 24h before use in the experiment. Virus construction was provided by Heyuan Biotechnology (Shanghai) Co., Ltd.

[0098] 2. Western blot was used to detect the effect of GNG2 overexpression on cardiomyocyte apoptosis indicators after hypoxia.

[0099] The apoptosis marker proteins were cleaved caspase3 (Abcam), Bax (Proteintech), and Bcl2 (Abcam). The specific method was the same as in Example 1.

[0100] The results showed that compared with the AdNC group, the expression of pro-apoptotic indexes cleaved caspase3 and Bax in the AdNC+CoCl2 group was significantly increased, and the anti-apoptotic index Bcl2 was significantly decreased. Compared with the AdNC+CoCl2 group, the expression of pro-apoptotic indexes cleaved caspase3 and Bax in the AdGNG2+CoCl2 group was significantly decreased, and the anti-apoptotic index Bcl2 was significantly increased ( Figure 3 AE).

[0101] 3. TUNEL staining was used to detect the effect of GNG2 overexpression on H9C2 cardiomyocyte apoptosis.

[0102] (1) Washing: Discard the culture medium and add PBS to wash twice, 5 min each time.

[0103] (2) Fixation: Add fixative and fix at 4°C for 30 min.

[0104] (3) Washing: Add PBS and wash twice, 5 minutes each time. Gently discard the PBS and absorb the excess liquid with filter paper.

[0105] (4) Permeabilization: Add permeabilization solution and incubate at room temperature for 5 min.

[0106] (5) Washing: Add PBS and wash twice, 5 minutes each time. Gently discard the PBS.

[0107] (6) Add 50 μL TUNEL working solution and incubate at 37°C in the dark for 60 min. Add PBS and wash three times. Add anti-fluorescence quenching sealing solution and observe the fluorescence effect under a fluorescence microscope.

[0108] The results showed that compared with the AdNC group, the apoptotic rate of H9C2 cardiomyocytes in the AdNC+CoCl2 group was significantly increased. Compared with the AdNC+CoCl2 group, the number of apoptotic cells in the H9C2 cardiomyocytes in the AdGNG2+CoCl2 group was significantly reduced ( Figure 3 F, G).

[0109] Example 4: GNG2 knockdown promotes cardiomyocyte apoptosis after hypoxia.

[0110] 1. Establishment of low expression of GNG2 and hypoxia model in H9C2 cardiomyocytes.

[0111] In order to prepare H9C2 cardiomyocytes with low expression of GNG2, the cells were plated in six-well plates and transfected with siRNA when the cells grew to 70%~80%. The sequence was 5'-3': GAAGAGGUAUUGAAUGCUA; 3'-5': CUUCUCCAUAACUUACGAU. 0.5mL Opti-MEM medium was added to each well, and siNC and siGNG2 were transfected into rat H9C2 cardiomyocytes using lipofectamine RNAiMAX transfection reagent. The cells were cultured in a cell culture incubator at 37℃ and 5% CO2 for 6~8h, and then the Opti-MEM in the six-well plates was replaced with DMEM medium containing 10% fetal bovine serum and 1% antibiotics, and 600µMCoCl2 was added. The cells were cultured for 24h before being used for experiments.

[0112] 2. Western blot was used to detect the effect of GNG2 overexpression on cardiomyocyte apoptosis indicators after hypoxia.

[0113] The apoptosis marker proteins were cleaved caspase3 (Abcam), Bax (Proteintech), and Bcl2 (Abcam). The specific method was the same as in Example 1.

[0114] The results showed that compared with the siNC group, the expression of pro-apoptotic indexes cleaved caspase3 and Bax in the siNC+CoCl2 group was significantly increased, and the anti-apoptotic index Bcl2 was significantly decreased. Compared with the siNC+CoCl2 group, the expression of pro-apoptotic indexes cleaved caspase3 and Bax in the siGNG2+CoCl2 group was significantly increased, and the anti-apoptotic index Bcl2 was significantly decreased ( Figure 4 AE).

[0115] 3. TUNEL staining was used to detect the effect of low expression of GNG2 on apoptosis of H9C2 cardiomyocytes. The specific steps are shown in Example 4.

[0116] The results showed that compared with the siNC group, the apoptotic rate of H9C2 cardiomyocytes in the siNC+CoCl2 group was significantly increased. Compared with the siNC+CoCl2 group, the number of apoptotic cells in the siGNG2+CoCl2 group was significantly increased ( Figure 4 F, G).

[0117] In summary, the present invention has proved through a large number of experiments that GNG2 expression is significantly increased in the AMI model. The GNG2 overexpression or underexpression model in mice was constructed by tail vein injection of AAV virus, and it was found that overexpression of GNG2 in mice significantly improved cardiac function after AMI. In in vitro cytology, when H9C2 / NRCMs were given CoCl2 hypoxia stimulation, GNG2 protein expression was significantly increased. Low expression of GNG2 promotes hypoxia-induced cardiomyocyte apoptosis; conversely, overexpression of GNG2 inhibits hypoxia-induced cardiomyocyte apoptosis. The above results show that GNG2 plays an important regulatory role in the occurrence and development of AMI and may be a new target for the prevention or treatment of AMI.

[0118] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A drug for treating the prognosis of acute myocardial infarction, characterized in that: The medicine includes an agent for increasing the expression level of the GNG2 gene or protein.

2. The drug according to claim 1, characterized in that The reagent for increasing the expression level of the GNG2 gene or protein includes the GNG2 gene, or a plasmid containing the GNG2 gene coding region, or a recombinant vector containing the GNG2 gene coding region, or a host bacteria containing the recombinant vector, or a cell containing the recombinant vector.

3. The drug according to claim 1, characterized in that The drug also includes a pharmaceutically acceptable carrier; the dosage form of the drug is a pharmaceutically acceptable dosage form.

4. A reagent for inhibiting apoptosis of myocardial cells after hypoxia, characterized in that: The reagents include reagents for increasing the expression level of the GNG2 gene or protein.

5. The drug according to claim 4, characterized in that The reagent for increasing the expression level of the GNG2 gene or protein includes the GNG2 gene, or a plasmid containing the GNG2 gene coding region, or a recombinant vector containing the GNG2 gene coding region, or a host bacteria containing the recombinant vector, or a cell containing the recombinant vector.

6. A reagent for promoting apoptosis of myocardial cells after hypoxia, characterized in that: The reagents include reagents that inhibit the expression of the GNG2 gene or protein.

7. The use according to claim 6, characterized in that: The reagent for inhibiting the expression of the GNG2 gene or protein includes siRNA specifically targeting the GNG2 gene, and the nucleotide sequence of the siRNA is shown in SEQ ID NO.

5.

8. Use of a detection reagent for the expression level of the GNG2 gene or its encoded protein in the preparation of an auxiliary diagnosis product for acute myocardial infarction.

9. The use according to claim 8, characterized in that: The product detects the expression level of the GNG2 gene or its encoded protein in a sample by reverse transcription PCR, real-time quantitative PCR, chip, high-throughput sequencing platform, immunohistochemical staining or enzyme-linked immunosorbent assay.

10. The use according to claim 8, characterized in that: The product contains specific primers for amplifying the GNG2 gene, a probe that hybridizes with the nucleotide sequence of the GNG2 gene, or an antibody that specifically binds to the GNG2 protein; the specific primer sequence of the GNG2 gene is as shown in SEQ ID NO.1~2.